Aileron Therapeutics Inc. [NASDAQ: ALRN] price surged by 13.19 percent to reach at $0.19. The company report on March 4, 2021 that Aileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference.
Aileron Therapeutics (NASDAQ:ALRN) announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the 2021 H.C. Wainwright Global Life Sciences Conference, which is taking place March 9 – 10, 2021. Dr. Aivado’s presentation will include an overview of Aileron’s upcoming Phase 1b placebo-controlled trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer, anticipated to begin in the second quarter of 2021, including the company’s target enrollment expansion announced earlier this week.
A webcast of the presentation will be available on demand under the Investors and Media section of Aileron’s website at https://investors.aileronrx.com/ beginning March 9, 2021 at 7:00 a.m. EST. A replay of the webcast will be archived on Aileron’s website for 90 days following the event.
A sum of 3470791 shares traded at recent session while its average daily volume was at 4.32M shares. Aileron Therapeutics Inc. shares reached a high of $1.65 and dropped to a low of $1.385 until finishing in the latest session at $1.63.
Guru’s Opinion on Aileron Therapeutics Inc. [ALRN]:
William Blair have made an estimate for Aileron Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 24, 2017. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on July 24, 2017, representing the official price target for Aileron Therapeutics Inc. stock. Previously, the target price had yet another raise to $19, while BofA/Merrill analysts kept a Buy rating on ALRN stock.
The Average True Range (ATR) for Aileron Therapeutics Inc. is set at 0.17 The Price to Book ratio for the last quarter was 5.09, with the Price to Cash per share for the same quarter was set at 0.19.
ALRN Stock Performance Analysis:
Aileron Therapeutics Inc. [ALRN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 19.85. With this latest performance, ALRN shares dropped by -20.87% in over the last four-week period, additionally plugging by 34.71% over the last 6 months – not to mention a rise of 359.15% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALRN stock in for the last two-week period is set at 50.51, with the RSI for the last a single of trading hit 54.57, and the three-weeks RSI is set at 50.05 for Aileron Therapeutics Inc. [ALRN]. The present Moving Average for the last 50 days of trading for this stock 1.7239, while it was recorded at 1.4480 for the last single week of trading, and 1.3425 for the last 200 days.
Insight into Aileron Therapeutics Inc. Fundamentals:
Return on Total Capital for ALRN is now -130.18, given the latest momentum, and Return on Invested Capital for the company is -128.88. Return on Equity for this stock declined to -164.77, with Return on Assets sitting at -100.52. When it comes to the capital structure of this company, Aileron Therapeutics Inc. [ALRN] has a Total Debt to Total Equity ratio set at 31.36. Additionally, ALRN Total Debt to Total Capital is recorded at 23.87, with Total Debt to Total Assets ending up at 17.89. Long-Term Debt to Equity for the company is recorded at 28.58, with the Long-Term Debt to Total Capital now at 21.76.
Reflecting on the efficiency of the workforce at the company, Aileron Therapeutics Inc. [ALRN] managed to generate an average of -$2,259,154 per employee.Aileron Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.00 and a Current Ratio set at 3.00.
ALRN Stock EPS
With the latest financial reports released by the company, Aileron Therapeutics Inc. posted -0.26/share EPS, while the average EPS was predicted by analysts to be reported at -0.27/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 3.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALRN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Aileron Therapeutics Inc. go to 2.10%.
Aileron Therapeutics Inc. [ALRN] Insider Position Details
There are presently around $16 million, or 15.50% of ALRN stock, in the hands of institutional investors. The top three institutional holders of ALRN stocks are: SATTER MANAGEMENT CO., L.P. with ownership of 7,609,449, which is approximately New of the company’s market cap and around 31.56% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 634,381 shares of the stock with an approximate value of $1.03 million in ALRN stocks shares; and VANGUARD GROUP INC, currently with $0.72 million in ALRN stock with ownership of nearly 80.356% of the company’s market capitalization.
Positions in Aileron Therapeutics Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 17 institutional holders increased their position in Aileron Therapeutics Inc. [NASDAQ:ALRN] by around 8,266,229 shares. Additionally, 14 investors decreased positions by around 1,197,807 shares, while 9 investors held positions by with 390,535 shares. The mentioned changes placed institutional holdings at 9,854,571 shares, according to the latest SEC report filing. ALRN stock had 11 new institutional investments in for a total of 7,893,864 shares, while 11 institutional investors sold positions of 470,806 shares during the same period.